Inhalation of stem cell products in patients with covid-19
Early Phase 1
Recruiting
- Conditions
- covid-19.https://www.who.int/publications/m/item/covid-19-update-for-icd-10
- Registration Number
- IRCT20210919052520N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Patients with Covid 19 who have been infected for a week and who have been hospitalized for 48 hours despite receiving medication and oxygen have not improved their condition and their arterial blood oxygen saturation percentage is below 88%.
Exclusion Criteria
Patients with arterial blood oxygen saturation above 88%.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment of patients suffer from Covid 19 nebulization of conditioned-medium derived from human adipose tissue mesenchymal stem cell. Timepoint: Comparison of the improvement of patients with covid-19 disease before the intervention and after 5 days of therapeutic intervention. Method of measurement: blood laboratory test , CT-Scan.
- Secondary Outcome Measures
Name Time Method Reduction of lung damage. Timepoint: Measurement of lung damage before and after therapeutic intervention. Method of measurement: CT-Scan.;CRP, LDH, WBC measurement. Timepoint: Before and after therapeutic intervention. Method of measurement: blood laboratory test.;Fever. Timepoint: Before and after therapeutic intervention. Method of measurement: Thermometer.